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Normal hematopoiesis
Mobilization of hematopoietic stem cells as a result of innate
immunity-mediated sterile inflammation in the bone marrow
microenvironment—the involvement of extracellular nucleotides
and purinergic signaling
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Abstract
Hematopoietic stem/progenitor cells (HSPCs) circulate in peripheral blood (PB) under normal conditions and their number
increases in response to stress, inflammation, tissue/organ injury, and may increase up to 100-fold after administration of
mobilization-inducing drugs. Mounting evidence suggests that mobilizing agent-induced mobilization of HSPCs from bone
marrow into PB is a result of innate immunity-mediated sterile inflammation in the bone marrow (BM) microenvironment. A
critical initiating role in this process is played by tissue/organ injury-mediated or pharmacologically induced release from
bone marrow-residing granulocytes and monocytes of (i) danger-associated molecular patterns (DAMPs), (ii) reactive
oxygen species (ROS), and (iii) proteolytic and lipolytic enzymes. All these factors together trigger activation of the
complement and coagulation cascades, both of which orchestrate egress of HSPCs into BM sinusoids and lymphatics.
Recent evidence also indicates that, in addition to attenuation of the SDF-1–CXCR4 and VLA-4–VCAM-1 retention axes in
the BM microenvironment and the presence of a mobilization-directing phosphosphingolipid gradient in PB, an important
role in the mobilization process is played by extracellular nucleotides and purinergic signaling. In particular, a new finding
by our laboratory is that, while extracellular ATP promotes mobilization of HSPCs, its derivative, adenosine, has the
opposite (inhibitory) effect.
Introduction
Hematopoietic stem/progenitor cells (HSPCs) circulate in
peripheral blood (PB) under normal conditions following
circadian rhythm of circulation and their number increases
in response to stress, inflammation as well as tissue/organ
injury. The number of HSPCs in PB may increase up to
100-fold after administration of drugs that induce mobili-
zation [1–7]. Based on this, the pharmacological mobiliza-
tion of HSPCs has been exploited since several years as a
convenient strategy to obtain these cells for hematopoietic
reconstitution after hematopoietic transplant [6, 7]. The
obvious advantage of this strategy is that HSPCs mobilized
into PB are relatively easily accessible and they engraft fast
after transplantation. Several potential mechanisms have
been proposed to regulate mobilization, but still more work
is needed to shed more light on this process. Therefore, a
better mechanistic insight will help to develop more effi-
cient strategies to obtain these cells for clinical purposes.
Our groups since several years are studying a role of innate
immunity in this process [8–13].
HSPCs are retained in their niches in the bone marrow
(BM) microenvironment due to retention signals involving
mainly interaction of the CXCR4 and VLA-4 receptors
present on their surface with the corresponding ligands,
stromal-derived factor 1 (SDF-1), and vascular cell adhesion
molecule 1 (VCAM-1), respectively, which are expressed in
BM stem cell niches [1, 2]. The importance of both retention
axes is supported by the fact that blockade of either CXCR4
or VLA-4 by small-molecule antagonists triggers rapid
mobilization of HSPCs into PB [3, 4]. Mobilization of
HSPCs into PB is also triggered in response to strenuous
exercise, tissue/organ injury, and administration of certain
cytokines (granulocyte mobilizing factor, G-CSF) or che-
mokines (growth-regulated protein beta, Gro-beta) [4–7].
Evidence has accumulated that, in all of these cases, the
mobilizing agent induces a cascade of events in the BM
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microenvironment that can be considered as an example of
“sterile inflammation.” According to the definition, sterile
inflammation is an inflammatory process that occurs in a
given tissue in the absence of any microorganisms [8].
However, like microbial-induced inflammation, sterile
inflammation is marked by the activation of cellular and
soluble elements of innate immunity, including neutrophils
and macrophages as well as the complement cascade
(ComC) [8, 9]. In the first step of sterile inflammation,
activated granulocytes and monocytes residing in the BM
microenvironment release danger-associated molecular
pattern (DAMPs) molecules, reactive oxygen species
(ROS), proteolytic and lipolytic enzymes, and several pro-
inflammatory cytokines and chemokines [8–12]. Mediators
released during sterile inflammation, such as DAMPs and
ROS, activate ancient enzymatic proteolytic cascades in the
BM microenvironment, mainly the complement cascade
(ComC) [8, 11] but in addition also the coagulation cascade
(CoaC) [13–15]. Mice deficient in some elements of the
ComC (e.g., C5) are poor mobilizers of HSPCs [16, 17].
Clinical data also support an important role for ComC
activation during mobilization in patients [18].
Induction of sterile inflammation in BM is crucial for (i)
release of HSPCs from their niches, (ii) permeablization of
the BM–PB endothelial barrier, and (iii) egress of neu-
trophils and monocytes into PB in a process that paves the
way for HSPCs to follow the mobilizing gradient of
bioactive phosphosphingolipids (sphingosine-1-phosphate,
S1P, and ceramide-1-phosphate, C1P) originating in PB
[19–21]. Egress of HSPCs into lymphatics is also directed
by S1P and C1P [22].
The crucial role of S1P and C1P in the egress of HSPCs
is supported by the fact that both of these phospho-
sphingolipids create strong chemotactic gradients for
HSPCs across the BM–PB endothelial barrier already
under steady-state conditions [19]. The retention of HSPCs
in BM niches also indicates an active retention process for
HSPCs that counteracts these gradients. Furthermore, evi-
dence has accumulated that mobilization of HSPCs corre-
lates with the level of S1P in PB and is impaired in mice
that have low levels of S1P in PB due to sphingosine kinase
1 deficiency [20] and are enhanced in mice with sphingo-
sine 2 kinase deficiency, which, somewhat surprisingly,
have elevated levels of S1P in PB plasma [23].
In this editorial, we will present the mounting body of
evidence that an important trigger of sterile inflammation in
BM is the release of DAMPs and ROS from activated Gr-1+
granulocytes and monocytes. Both DAMPs and ROS are
major activators of the ComC by involving the mannan-
binding lectin (MBL) pathway of ComC activation [11].
The crucial DAMPs in this process are extracellular
nucleotides, such as ATP, which are released by pannexin
hemichannels expressed, e.g., on the cell membranes of
granulocytes and monocytes [8, 11]. Also, contributing to
this process are ROS released from these cells, and in the
BM microenvironment ROS-exposed neo-epitopes bind
naturally occurring antibodies (NAbs) [24]. Both DAMPs
and neoepitope–NAb complexes are recognized by MBL, a
soluble member of the class of innate immunity elements
known as pattern recognition receptors (PRRs) [8, 9, 11].
Activation of granulocytes and monocytes initiates
sterile inflammation in BM and triggers the
mobilization of HSPCs
A mounting body of evidence demonstrates the crucial
involvement of the ComC as well as granulocytes and
monocytes in triggering the mobilization of HSPCs (Fig. 1).
The pivotal role of Gr-1+ granulocytes and monocytes in
the mobilization process has already been well demon-
strated in elegant studies performed in mice [25, 26]. These
cells are important cellular components of innate immunity
and are activated in the BM microenvironment by promo-
bilizing signals released from damaged tissues as well as by
pharmacological agents employed for mobilization
of HSPCs. As depicted in Figs. 1 and 2, they are also first-
responder cells in initiating sterile inflammation by
secreting several proteolytic and lipolytic enzymes [27, 28]
Mobilizing Smuli
Inducon of Sterile Inflammaon in 
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Fig. 1 The ComC plays an important role in triggering the mobiliza-
tion of HSPCs in a mannan-binding lectin (MBL) pathway-dependent
manner. Promobilizing stimuli activate sterile inflammation in the BM
microenvironment and activation of the complement cascade (ComC),
which leads to C5 cleavage and the generation of C5a and desArgC5a
anaphylatoxins. Both of these C5 cleavage fragments facilitate egress
of HSPCs into PB in response to S1P and C1P gradients. Of the three
ComC activation pathways (classical, alternative, and mannan-binding
lectin, MBL), the MBL pathway plays as we reported [11] a crucial
role in the effect of sterile inflammation on the BM microenvironment
and activation of the ComC
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and—what is important for the topic of this review—also
DAMPs and ROS. While a role for proteolytic enzymes in
attenuating SDF-1–CXCR and VCAM-1–VLA interactions
between HSPCs and their niches has been proposed by
other groups [1, 2, 27], our recent evidence indicates that
the lipolytic enzyme phospholipase C β2 (PLC-β2), which
is released from granulocytes and digests glycosylpho-
sphatidylinositol anchor (GPI-A) in cell membranes, plays a
crucial role in the release of HSPCs from BM niches [28].
To explain this effect, CXCR4 and VLA-4 expressed on
HSPCs are incorporated into membrane lipid rafts for
optimal function [29], and by digesting GPI-A, PLC-β2
destroys the integrity of cell surface membrane lipid rafts
and thus attenuates HSPC retention in BM [28]. Cells
released from BM niches become susceptible to chemo-
tactic gradients of S1P and C1P that are present in BM
sinusoids [19–21].
However, according to the main point of this review, the
first step in the induction of sterile inflammation and acti-
vation of the ComC is the release of DAMPs by
granulocytes and monocytes [8, 11, 30–33]. The most
important DAMPs released from these cells upon their
activation by mobilizing cues are ATP [8, 11] and high
group mobility box 1 (HGMB-1) protein [8, 30] ATP is
secreted through cell surface pannexin hemichannels [8, 11,
30]. In support of this mechanism, we observed that inhi-
bition of pannexin 1 channels by probenecid results in
attenuation of the mobilization of HSPCs (manuscript in
preparation). It has also been reported that two other
mechanisms are responsible for DAMP release, one invol-
ving connexin 43 and the other involving extracellular
microvesicles (ExMVs) [8]. Interestingly, mice deficient in
connexin 43 have been reported to be poor mobilizers [34],
and a potential role of connexin 43 in ATP release may
additionally be responsible for the poor mobilization status
of these mice.
ATP is a well-known ubiquitous intracellular molecular
energy source, but in addition it may also be secreted into
the intercellular space, where it acts as an important sig-
naling molecule in purinergic signaling [35]. In contrast to
ATP, HGMB-1 is just a nuclear protein that binds DNA in a
non-sequence-specific manner and is involved in chromatin
remodeling and bending [8]. As mentioned above, both ATP
and HGMB-1 are recognized by a member of the class of
soluble PRRs, MBL [8, 11, 30–33]. After binding to
DAMPs, MBL activates the MBL-associated serine pro-
teases MASP-1 and -2, which initiate activation of the
ComC (Figs. 1 and 2). Of the three ComC activation path-
ways—classical, alternative, and MBL—the last plays as we
reported a pivotal role in the induction of sterile inflamma-
tion in BM and in triggering the mobilization of HSPCs. In
support of this mechanism, we recently reported that mice
deficient in MBL (MBL-KO mice) are poor mobilizers of
HSPCs [11]. By contrast, mice deficient in elements of the
classical pathway of ComC activation, such as C1q-KO
mice, are easy mobilizers [36]. Our indirect results also
indicate that a supportive role in the mobilization process is
played by the alternative pathway, as mice deficient in factor
B (an element of the alternative pathway of ComC activa-
tion) also show a defect in the mobilization process [37].
In parallel to DAMPs, activated granulocytes and
monocytes also release ROS, which, as mentioned above,
by oxidation of cell membranes on cells in the BM micro-
environment, expose neo-epitopes that are recognized by
NAbs of the IgM class. NAbs are produced without any
previous infection, vaccination, or other foreign antigen
exposure and are important soluble components of innate
immunity [9, 24]. Their physiological role is restricted to
acting as key regulators in recognizing neo-epitopes
exposed on the surface of damaged cells. As previously
demonstrated, such neoepitope–NAbs complexes are, like
DAMPs, recognized by MBL [24, 31] and activate the
ComC via MASP activation (Fig. 2).
Mobilizing Smuli
DAMPs ROS
ComC
Egress of HSPCs from BM
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Fig. 2 Proposed MBL-induced model for triggering sterile inflamma-
tion in BM. A mobilizing agent (e.g., G-CSF) induces secretion of
DAMP molecules (e.g., ATP) and ROS from Gr-1+ cells (granulocytes
or monocytes). ATP directly and ROS indirectly (by exposing neoe-
pitope antigens in the BM microenvironment that are recognized by
naturally occurring antibodies [Nabs] to form neoepitope–NAbs
complexes) are recognized by MBL, which initiates activation of the
ComC in a MBL-MASPs-dependent manner. The C5 cleavage frag-
ments, anaphylatoxins C5a and desArgC5a, facilitate egress of HSPCs
from BM into PB by augmenting further degranulation of granulocytes
and attenuating BM-retention axes in the stem cell niches (by release
of proteolytic and lipolytic enzymes) and chemoattracting granulo-
cytes and monocytes into PB to pave the way for HSPC migration
across the BM–PB barrier. As a result, HSPCs released from their
niches follow the S1P and C1P gradients originating in PB. In parallel,
MASP-1 also activates the CoaC. Egress of HSPCs from BM into PB
is negatively regulated by the anti-inflammatory action of HO-1 and
adenosine. In red color is highlighted ATP released from Gr-1+ cells
as DAMP—that promotes mobilization and its degradation product
adenosine—that has an opposite effect on mobilization process
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Of the two MASPs present in serum (MASP-1 and -2),
MASP-1 seems to play a crucial role in activating the
ComC [32]. In addition, MASP-1 is also involved in acti-
vation of the CoaC by activating prothrombin to thrombin,
which explains why both cascades are activated in parallel
during the mobilization process [13–15]. Moreover, it has
been reported that, during the coagulation process, thrombin
exhibits C5 convertase-like activity [38]. Therefore, the
evidence indicates that coordinated crosstalk between both
cascades potentiates activation of the distal part of the
ComC by cleavage of C5 into the bioactive C5a and
desArgC5a anaphylatoxins. In case of a deficiency of the
proximal C3 complement component, thrombin C5
convertase-like activity may also replace the function of
classical C5 convertase activity provided by activated C3
cleavage fragments [13]. This demonstrates the presence of
redundancy in supplying C5 convertase activity by both the
ComC (in its classical form) and the CoaC (in its “activity-
like” form). Further supporting this involvement of the
CoaC in the mobilization process, exposure of mice to the
thrombin inhibitor heparin has a negative effect on G-CSF-
or AMD3100-induced egress of HSPCs from BM into PB
[13]. This is not surprising, given that the inflammation and
coagulation processes are activated in parallel by similar
stimuli [8, 9].
Based on this mechanism, the final step of sterile
inflammation in the BM microenvironment and in activa-
tion of the ComC and CoaC during the mobilization of
HSPCs is cleavage of C5 into C5a and desArgC5a. In fact,
mice that are deficient in C5 are poor mobilizers [16]. This
strongly supports a requirement for C5 cleavage and the
generation of two important anaphylatoxins, C5a and
desArgC5a, in the egress of HSPCs from BM into PB [16].
What is also interesting, mice that are deficient in the C5
component of the ComC do not also display circadian
changes in circulation of HSPCs in blood [39]. The open
question is whether this circadian release of HSPCs reflects
induction of circadian peaks of sterile inflammation in the
BM microenvironment due to deep-sleep hypoxia [39]. In
fact, circadian activation of the ComC has been demon-
strated by other investigators [40].
The emerging role of extracellular nucleotides and
purinergic signaling in initiating sterile
inflammation in the BM microenvironment
As mentioned above, ATP secreted from G-CSF-activated
neutrophils and monocytes is a crucial DAMP molecule
involved in induction of sterile inflammation in BM during
the mobilization of HSPCs, leading to ComC activation in
an MBL-dependent manner [11]. However, besides serving
as a DAMP ligand for MBL, ATP is also involved as part of
purinergic signaling in initiating several other pathways
controlling release of HSPCs from BM into PB that are still
not completely understood [35]. Biological effects of ATP
and other extracellular nucleotides as part of purinergic
signaling in BM have been reported for normal and leu-
kemic cells [41, 42]. In addition to hematopoietic cells,
extracellular nucleotides and purinergic signaling also
modulate the function of other BM components, including
mesenchymal cells and endothelial cells [41]. Thus, in
addition to the relatively well-studied effects of peptide-
based growth factors, cytokines, and chemokines, small-
molecule extracellular nucleotides add significant diversity
to the collection of known players in sterile inflammation
and are necessary to better understand the development of
pre-natal [43] and post-natal hematopoiesis [41] as well as
stem cell trafficking [41, 42].
Overall, purinergic signaling is an evolutionarily ancient
signaling mechanism regulating several aspects of cell
biology, such as the generation of chemotactic signals and
modulation of the responsiveness of innate and acquired
immune cells to inflammatory cues [35]. Purinergic signal-
ing is involved in homeostasis of the organism and regulates
neurotransmission, cardiac and vascular function, platelet
aggregation, and hematopoiesis [35]. These pleiotropic
functions are regulated by ATP and its metabolites, such as
ADP, AMP, and the nucleoside adenosine, as well as by
other nucleotides such as the pyrimidine nucleotides UTP,
UDP, and certain nucleotide derivatives like UDP-glucose
[35, 41]. After many years of skepticism, purinergic sig-
naling is now widely acknowledged, and several cell surface
receptors have been cloned and shown to be expressed on
cells in almost every tissue in the body [35, 41].
On the surfaces of hematopoietic cells we can distinguish
the expression of both nucleotide- and nucleoside-activated
receptors, which belong to two different purinergic receptor
families, P2 and P1 [41]. P2 receptors are further sub-
divided into metabotropic (P2Y) and ionotropic channel
(P2X) receptors based on structural characteristics [35, 41].
The P2Y receptor family, including eight receptors that
have been identified so far (P2Y1, 2, 4, 6, 11, 12, 13, and
14), are G protein-coupled receptors and respond to sti-
mulation by ATP, ADP, UTP, UDP, and UDP-glucose [41].
The P2X ionotropic channel receptor family consists of
seven members (P2X1, 2, 3, 4, 5, 6, and 7), which are
activated by ATP, opening the channel to allow an influx
of Ca2+, Na+, and K+[35, 41]. The P1 receptor family
consists of four G protein-coupled receptor subtypes, A1,
A2A, A2B, and A3, which are activated by adenosine and its
analogs [35, 41].
This large number of receptors and ligands shows the
complexity of the purinergic signaling system. It also
indicates that ATP, being a major DAMP molecule secreted
by activated neutrophils and monocytes and a trigger for
MBL-mediated activation of the ComC, may also affect
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several other responses in cells within the hematopoietic
microenvironment by interacting with the corresponding
purinergic receptors [41]. Furthermore, processing of
ATP in the extracellular space by ectonucleotidases such
as CD39 and CD73, leading to generation of the ATP
metabolites ADP, AMP, and adenosine, generates new
bioactive signaling molecules in the extracellular space [41,
44]. Also present in the extracellular space are other med-
iators of purinergic signaling, such as UTP and UDP [35,
41, 42]. In addition to the DAMP activity of ATP, evidence
suggests that there are effects of extracellular nucleotides
in mobilization that are not directly mediated by ATP.
For example, mice exposed to UDP-glucose, which
directly activates the P2Y14 receptor, mobilize long-term
repopulating hematopoietic stem cells into peripheral
blood, and animals that are P2Y14 deficient display
accelerated senescence of HSPCs in response to radiation
stress, chemotherapy, and the normal physiological aging
process [44].
Interestingly, our most recent results indicate that, while
injection of ATP enhances the mobilization of HSPCs, its
final metabolite adenosine has the opposite effect (manu-
script in preparation). Adenosine is well known for its
immunosuppressive and anti-inflammatory effects [45].
Given that mobilization of HSPCs requires the induction of
sterile inflammation in the BM microenvironment, an anti-
inflammatory effect of adenosine explains this inhibitory
phenomenon. Moreover, ATP is released by cells at much
higher concentrations than UDP-glucose, which indicates a
more important role for this extracellular nucleotide in the
mobilization process [8, 44]. Moreover, since ATP does not
interact with the P2Y14 receptor [44], this suggests that
ATP may influence the mobilization process through means
other than its DAMP activity by interacting with other
receptors of the purinergic signaling family.
More work is also needed to phenotype BM stem cell
niches for the expression of purinergic receptors. However,
the hematopoietic stem cell niche remains incompletely
defined and is described by competing models [46, 47].
Recent research indicates that this niche is perivascular
(SDF-1+ and KL+), created partially by mesenchymal
stromal cells and endothelial cells, and is often, but not
always, located near trabecular bone [46]. While HSCs are
located around perivascular cells, it has been proposed that
early lymphoid progenitors are associated with the osteo-
blastic niche [46]. Moreover, the existence of distinct niches
for distinct subpopulations of HSCs, including quiescent
nestinbright NG2+ arteriolar and proliferative nestindimLepr+
sinusoidal niches, have also been proposed [46, 47].
Overall, the effect of purinergic signaling in maintaining the
integrity of these niches under steady-state conditions and
during mobilization requires further study. Furthermore,
given the role of osteoclasts in mobilization [48],
extracellular nucleotides may affect the biological functions
of these cells.
In particular, since it has been proposed that beta-
adrenergic signaling is involved in egress of HSPCs into
circulation [49] and because purinergic signaling is
involved in addition to catecholamine and acetylcholine in
neurotransmission [35], further studies are needed to
explain the potential interaction between purinergic signal-
ing and the signaling of other neurotransmitters in the
mobilization process. As mentioned above, it will also be
interesting to see the effect of extracellular nucleotides on
the circadian rhythm of stem cell release from BM into PB.
Based on all of these considerations, the involvement of
purinergic signaling in maintaining normal and stress-
induced hematopoiesis needs reappraisal. This is a viable
task, particularly since additional KO animal models are
now available. Moreover, several new and more-specific
small-molecule modulators of purinergic receptor family
signaling as well as CD39 and CD73 ectonucleotidases that
degrade ATP in the extracellular space to its active meta-
bolites, including adenosine, are now available.
Inhibitors of sterile inflammation as negative
regulators of HSPC mobilization
Since the induction of sterile inflammation is crucial in
triggering the HSPC mobilization process [11], an anti-
inflammatory treatment will have the opposite effect. As
mentioned above, the extracellular ATP degradation pro-
duct adenosine is an important known anti-inflammatory
mediator [45], which, as we recently observed, inhibits
egress of HSPCs into PB. Since adenosine is generated in
the extracellular space by CD73 ectonucleotidase, we
expect that CD73-KO mice, which do not process conver-
sion of AMP to adenosine in the extracellular space, should
be easy mobilizers.
Another important inhibitor of stem cell mobilization that
counteracts BM sterile inflammation is heme oxygenase 1
(HO-1), and one of its demonstrated effects is inhibition of
cell migration [50]. HO-1 is an inducible enzyme that is
upregulated in the BM microenvironment in response to
several oxidative stress stimuli [51–55]. The anti-
inflammatory and anti-ComC activation effects of HO-1
have been very well demonstrated in an HO-1-deficient
mouse model as well as in a case of human HO-1 defi-
ciency. In both of these cases, the ComC becomes hyper-
activated due to the lack of a balancing inhibitory effect by
HO-1 [54]. Demonstrating an inhibitory effect of HO-1 on
stem cell mobilization, we have reported that (i) HO-1-
deficient mice are easy mobilizers of HSPCs [52], and (ii)
upregulation of HO-1 in hematopoietic cell lines by
employing small-molecule activators decreases cell che-
motaxis, while intracellular downregulation of HO-1 has the
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opposite effect [52]. We observed similar effects when
modifying the expression of HO-1 in normal murine and
human cells enriched for HSPCs [52, 56].
Based on this logic, inhibition of adenosine generation in
the BM extracellular space, for example, by inhibition of
the ectonucleotidase CD73 expressed on the surface of BM
cells or downregulation of HO-1 by employing small-
molecule inhibitors of this enzyme, should promote sterile
inflammation in the BM microenvironment, and facilitate
egress of HSPCs from BM into PB. Future work is also
needed to see how extracellular nucleotide and purinergic
signaling affect expression of CD73 and HO-1 in BM and
which receptors involved in those effects are potential
therapeutic targets.
Conclusions
We propose a crucial role for innate immunity-mediated
sterile inflammation induced in the BM microenvironment
by mobilization-inducing stimuli as a major driving force in
the egress of HSPCs across the BM–PB endothelial barrier
into the BM sinusoids. A parallel process most likely directs
the egress of HSPCs into lymphatics.
Recent evidence indicates that the onset of sterile
inflammation in BM is tightly connected with an increase in
the level of extracellular nucleotides, mainly ATP, which,
as a DAMP molecule, activates the ComC in an MBL-
dependent manner [11]. This effect does not preclude an
additional role of ATP and its degradation products (ADP,
AMP, and adenosine) in a non-DAMP-related modulation
of this process. In addition to Gr-1+ cells ATP may be also
released from other hematopoietic and non-hematopoietic
cells in BM upon their activation or in response to damage.
The release mechanism involved appears to be based on a
combination of vesicular exocytosis and involvement of
pannexin and connexin hemichannels. The expression and
abundance of functional purinergic receptors expressed on
HSPCs and other type of cells in the BM microenvironment
including perivascular SDF-1+ and KL+ mesenchymal
stromal cells and endothelial cells as well as cells in
quiescent nestinbright NG2+ arteriolar and proliferative nes-
tindimLepr+ sinusoidal niches, opens up a new area of
investigation to better understand the complexity of this
process, which will be crucial in designing more efficient
mobilization strategies. Furthermore, given the role of
osteoclasts in mobilization [48], extracellular nucleotides
may affect the biological functions of these cells as well.
More work is also needed to understand a role of purinergic
signaling as neurotransmitters in neural fibers in innervating
BM tissue [35] and its potential effect on modulation of
beta-adrenergic regulation of HSPCs mobilization [49].
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